Zolimomab aritox

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Zolimomab aritox ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD5
Clinical data
Legal status ?
Identifiers
CAS number 141483-72-9 N
ATC code None
KEGG D06381 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus[1] and graft-versus-host disease,[2] but the studies failed to show positive effects of the drug.

It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).[3]

See also[edit]

References[edit]

  1. ^ Stafford, FJ; Fleisher, TA; Lee, G; Brown, M; Strand, V; Austin Ha, 3rd; Balow, JE; Klippel, JH (1994). "A pilot study of anti-CD5 ricin a chain immunoconjugate in systemic lupus erythematosus". The Journal of rheumatology 21 (11): 2068–70. PMID 7532717. 
  2. ^ Przepiorka, D; Lemaistre, CF; Huh, YO; Luna, M; Saria, EA; Brown, CT; Champlin, RE (1994). "Evaluation of anti-CD5 ricin a chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic immunology 1 (2): 77–82. PMID 7584486. 
  3. ^ WHO Drug Information